Write in a clean editor, then format for Future Prescriber in one click — DocuGuru applies the official Wiley template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Future Prescriber is a peer-reviewed journal published by Wiley, covering Diabetes Treatment and Management, Rheumatoid Arthritis Research and Therapies, Pharmaceutical Economics and Policy.
| Publisher | Wiley |
|---|---|
| Reference style | Author–year (Chicago) Author–year — (Smith, 2023) in the text Smith, Ada, Ben Jones, and Cara Lee. 2023. "A Representative Article Title." Future Prescriber 12 (3): 45–58.
Formats any DOI in Future Prescriber style. No sign-up. |
| Publishes research in | Diabetes Treatment and Management Rheumatoid Arthritis Research and Therapies Pharmaceutical Economics and Policy Systemic Lupus Erythematosus Research Atrial Fibrillation Management and Outcomes |
| ISSN | 1468-9871 |
| h-index | 4 |
| i10-index | 1 |
| Total citations | 89 |
| Top institutions publishing here | Heart of England NHS Foundation Trust |
| Journal website | www.escriber.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Abstract Injection has long since been a barrier to insulin use. However, previous attempts to produce an inhaled insulin have met with difficulty. Technosphere insulin is a new system for delivery of inhaled insulin and is currently under review by the FDA. In this Drug profile, the authors discuss the technology and review the clinical…
Abstract Lixisenatide and albiglutide are glucagon‐like peptide‐1 (GLP‐1) agonists in clinical development that are similar to exenatide and liraglutide. This review critically considers the emerging evidence on the pharmacology, efficacy, safety and potential roles these two agents may have in clinical practice.
Abstract Gliptins represent an emerging new class of oral agents to treat type 2 diabetes. They act by inhibiting the enzyme dipeptidyl peptidase‐4 (DPP‐4). This enzyme inactivates the incretin hormones glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP). These hormones are released from the intestine during a meal and act on the pancreas to increase…
Abstract Type 2 diabetes mellitus (T2DM) is a major challenge to healthcare systems around the world, with an estimated prevalence of 6% (246 million) in 2007 rising to 7.3% (380 million) in 2025 worldwide.1–5 In this article, the authors consider the significance of the GLP‐1 path‐way in the management of T2DM, and some of the…
